Elevated levels of serum amyloid A indicate poor prognosis in patients with esophageal squamous cell carcinoma

Abstract

Abstract Background Increase of Serum amyloid A (SAA) level has been observed in patients with a variety of cancers. The objective of this study was to determined whether SAA level could be used as a prognostic parameter in patients with esophageal squamous cell carcinoma (ESCC). Methods SAA levels were measured by rate nephelometry immunoassay in 167 healthy controls and 167 ESCC patients prior to surgical resection. Statistical associations between clinicopathological observations and SAA levels were determined using the Mann–Whitney U test. The clinical value of SAA level as a prognostic parameter was evaluated using the Cox’s proportional hazards model. Results SAA levels were significantly higher in patients with ESCC compared to levels in healthy controls (13.88 ± 15.19 mg/L vs. 2.26 ± 1.66 mg/L, P P P = 0.015), T classification (P P P P P Conclusions An elevated level of preoperative SAA was found to associate with tumor progression and poor survival in patients with ESCC.

Keywords

• Serum amyloid A
• Esophageal squamous cell carcinoma
• Prognosis
• Biomark